• The number of patients who benefited from treatments in 2024 increased by 8%, reaching 66 million.
• Investments in research and development increase to EUR 6.2 billion, representing 23.2% of the net sales of the group.
• The company is preparing for the launch of new products starting with 2025.
Boehringer Ingelheim announced a continuous increase in the number of patients treated, reaching 66 million in 2024, 8.0% more than the previous year. The development of the current product portfolio is on the right track, the company preparing several launches of new products starting with 2025. Investments in research & development (C&D) have increased to EUR 6.2 billion, representing 23.2% of the group’s net sales. The net sales of the group increased by 6.1%* reaching EUR 26.8 billion.
“As our current portfolio is approaching the maturity phase and several products are approaching a potential launch on the market, we have entered an essential phase of major investments, to bring these innovations to patients,” said Hubertus von Baumbach, president of the Board of Directors. “It is important to use each opportunity to bring these new treatments to patients as soon as possible – this is our number one priority.”
“The results of 2024 reflect the Boehringer Ingelheim’s commitment to bring innovation closer to the patients, and Romania is part of this global effort. We are proud that, through our solid portfolio and continuous investments in research and development, we manage to respond to major medical needs and to prepare the launch of some revolutionary therapies and to the Romanian market. Contribute to a healthy health system, ”said Vasiliki Tsagkaraki, general manager and director of Human Pharma at Boehringer Ingelheim Romania.
Human Pharma: Investments in existing products and launches
Sales of Human Pharma division increased by 7.0%* reaching EUR 21.9 billion, being supported by Jardiance® and Offer. Jardiance® sales, now available for the treatment of chronic kidney disease, in addition to type 2 diabetes and heart failure, increased by 14.6%, reaching EUR 8.4 billion. OFV®, used for the treatment of idiopathic pulmonary fibrosis and certain fibrous interstitial interstitial diseases, has increased 8.9%, reaching EUR 3.8 billion.
The Human Pharma product portfolio includes over ten clinical studies in phases II and III planned for the next 12-18 months, with the potential of significant launches in the next five years. The expenses for C&D in Human Pharma increased to EUR 5.7 billion, ie 27.6% of the net sales of the business unit.
“If we look at the last five years, Boehringer Ingelheim has invested about EUR 25 billion in C&D,” said Frank Hübler, a member of the Board responsible for Finance. “With the innovations currently in the portfolio, we will continue to increase investments in C&D in the coming years.”
Following positive results from essential clinical trials, the company is preparing for the launch of several new products, starting this year, including the potential launches of Zungertinib and Nerandomilast.
Nerandomilast has the potential to improve treatment for patients with idiopathic pulmonary fibrosis (fibroneer -IP) and progressive pulmonary fibrosis (fibroneer -ild). The complete data from both Fibroneer ™ clinical studies in phase III, which have achieved their main objective, will be presented in the following months.
If approved, Zongerinib will be the first targeted, orally administered therapy for Her2-Mutant Pulmonary Cancer patients. The development of Zongertinib has been accelerated due to the positive results from the 1B long-1 beamy study, which showed a 71% response rate (CI 95%, 60–80), P
Both products, Zongertinib and Nerandomilast, have been submitted for approval to the regulatory authorities globally, and the first launches in the US are anticipated in the second half of this year, depending on approval.
Animal Health: Rapid response against cross -border diseases
The sales of the Health Animal Division increased by 1.9%, reaching EUR 4.7 billion in 2024, supported mainly by pets, therapeutic, birds and ruminant. Nexgard® parasiticides have strengthened their position with the largest sales in the industry, increasing by 14.0%, to EUR 1.4 billion.
Last year, Boehringer Ingelheim supported animal producers and governments by rapidly providing vaccines and technical assistance in the outbreaks of cross -border diseases (TAD), such as avian influenza, blue tongue virus and aphthous fever. These diseases are a major risk to animal health, prevent global trade, and constrain food supply.
Sustainable development
Boehringer Ingelheim is in the graph to achieve the carbon emissions neutrality goal in the company’s operations (SCOPE 1 and 2) by 2030. In 2024, electricity purchases from renewable sources increased to about 75%, due to the transition to renewable solutions in various locations, including Japan and China. A new biomass plant was put into operation at the headquarters in Ingelheim, Germany, to increase the generation of renewable energy on the spot up to 95% of the energy needs.
As part of his global effort to stop rabia, the company provided 46 million doses of anti -ro -storage vaccine and has supported vaccination campaigns in endemic countries. The initiative “Angels”, which aims to optimize the quality of treatment in existing centers for stroke, has added over 1,000 network organizations. This is the largest fight against stroke in the world, bringing together 237,000 health professionals from over 9,000 hospitals in 158 countries and has so far helped 19 million stroke patients.
Perspectives
Last year’s general trends and developments are expected to continue in 2025. The company envisages a continuous increase in the number of patients treated, as well as a slight annual net sales increase, adjusted for foreign and exceptional effects.
Boehringer Ingelheim
Boehringer Ingelheim is an active biopharmaceutical company in both human health and animal health. Being one of the largest investors in the research and development industry, the company focuses on the development of innovative therapies that can improve and extend life in areas with high and unsatisfied medical needs. Independent since its establishment in 1885, Boehringer adopted a long -term perspective, integrating sustainability throughout the value chain. About 54,500 employees serve over 130 markets to build a healthier and more sustainable future. Find out more on: Boehringer Ingelheim – Life Forward | Boehringer Ingelheim.
